Prelude Therapeutics Incorporated (PRLD)
NASDAQ: PRLD · Real-Time Price · USD
0.7523
+0.0583 (8.40%)
Apr 15, 2025, 4:00 PM EDT - Market closed
Prelude Therapeutics Revenue
In the year 2024, Prelude Therapeutics had annual revenue of $7.00M. Prelude Therapeutics had revenue of $4.00M in the quarter ending December 31, 2024.
Revenue (ttm)
$7.00M
Revenue Growth
n/a
P/S Ratio
7.52
Revenue / Employee
$53,435
Employees
131
Market Cap
41.49M
Revenue Chart
Revenue History
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
UnitedHealth Group | 400.28B |
Johnson & Johnson | 88.82B |
Merck & Co. | 64.17B |
AbbVie | 56.33B |
AstraZeneca | 54.07B |
Novartis AG | 51.72B |
Eli Lilly and Company | 45.04B |
Thermo Fisher Scientific | 42.88B |
PRLD News
- 5 weeks ago - Prelude Therapeutics Reports Full Year 2024 Financial Results and Provides Program Outlook for 2025 - GlobeNewsWire
- 5 weeks ago - Prelude Therapeutics to Participate in Barclays 27th Annual Global Healthcare Conference - GlobeNewsWire
- 4 months ago - Prelude Therapeutics Presents Preliminary Results of Phase 1 Dose-escalation Study of PRT2527 as Monotherapy and in Combination with Zanubrutinib in Patients with Relapsed/Refractory Lymphoid Malignancies - GlobeNewsWire
- 4 months ago - Prelude Therapeutics to Participate in Citizens JMP Securities Hematology and Oncology Summit - GlobeNewsWire
- 6 months ago - Prelude Therapeutics Presents New Data from SMARCA Degrader Portfolio at the 36th EORTC-NCI-AACR Symposium - GlobeNewsWire
- 6 months ago - Prelude Therapeutics Announces Publication of Abstracts for Presentation at the 36th EORTC-NCI-AACR Symposium - GlobeNewsWire
- 7 months ago - Prelude Therapeutics' SMARCA2 Degrader PRT3789 Demonstrated Promising Initial Clinical Activity and Safety Profile in Phase 1 Trial - GlobeNewsWire
- 7 months ago - Prelude Therapeutics Announces Publication of Abstract for Presentation at the European Society of Medical Oncology (ESMO) Congress 2024 - GlobeNewsWire